We previously revealed an interaction of KRAS/TP53 mutations in nonsquamous NSCLC, where we observed similarly poor progression-free survival (PFS) in the patients with no or single mutation, but significant PFS advantage in the co-mutant ones16, which indicates that only when these two mutations occur simultaneously, may they predict remarkable benefits from ICIs. Here, KRAS is linked to non-small cell lung carcinoma.